On Tuesday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, scientists and global health experts focused on malaria eradication, Agence France-Presse reports. “Key among the strategies … is the development of an effective anti-malaria vaccine, a project scientists have been researching since the late 80s. … RTS,S is the most clinically advanced malaria vaccine so far, according to the Malaria Vaccine Initiative,” the news service writes (11/3).
Kaiser Family Foundation Looks AtÂ Views On The U.S. Role In Global Health As a follow-up to a survey conducted in May 2009, this poll examines Americans’ attitudes toward U.S. global health investments and priorities. Some key findings include: the majority of Americans support maintaining (32%) or increasing (34%) spending on…
TIME reports on evidence along the Thai-Cambodia border that the malaria parasite is gaining resistance to artemisinin â€“ “the only remaining effective drug in the world’s arsenal against malaria’s most deadly strain.”
In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports.
“Two years after some $22 million in donor funds were pumped into malaria control along the Cambodia-Thailand border to fight off suspected resistance to treatment, health workers say the battle is not over,” IRIN reports, adding, “The government reported 103,000 malaria infections and 151 deaths nationwide in 2010. A year later, 85,000 reported infections led to 93 deaths — a 38-percent decline in mortality.” “‘If you take your foot off the â€¦ [accelerator] we can lose everything we have done in the past two to three years,’ Steven Bjorge, anti-malaria team leader in Cambodia for the [WHO], told IRIN in February 2012,” the news service writes.
“Drug-resistant strains of gonorrhea have spread to countries across the world, the U.N. health agency said on Wednesday, and millions of patients may run out of treatment options unless doctors catch and treat cases earlier,” Reuters reports (Kelland, 6/6). “Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics — the last treatment option against gonorrhea,” a WHO press release states (6/6).
“One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic,” the Associated Press reports (Wong, 6/7). “‘In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,’ said the study in the New England Journal of Medicine,” Agence France-Presse reports, adding, “Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study” (6/6).
“Researchers who tested a novel type of antibiotic against multi-drug-resistant tuberculosis [MDR-TB] are reporting that nearly half of patients who got the new drug cleared the bacteria from their lung fluid in two months,” according to a study published Thursday in the New England Journal of Medicine, Reuters reports. Japanese pharmaceutical company Otsuka developed the experimental drug, delamanid, and “also designed and financed the clinical trial, which took place in 17 medical centers across nine countries,” the news service writes (Emery, 6/6).
Noting that the “[r]oll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance,” Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues “call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs” in this BMJ analysis. “In sub-Saharan Africa, the region with the highest HIV/AIDS burden, high-level political commitment and substantial international funding have led to an unparalleled scale-up of access to treatment over the past eight years,” they write, adding, “However, little attention has been paid to the potential emergence and spread of drug-resistant HIV and its public health implications.”
The Wall Street Journal reports on a rise of multi-drug resistant tuberculosis (TB) in India, writing, “India’s slow response to years of medical warnings now threatens to turn the country into an incubator for a mutant strain of tuberculosis that is proving resistant to all known treatments, raising alarms of a new global health hazard.” The newspaper continues, “Spread of the strain could return tuberculosis to the fatal plague that killed two-thirds of people afflicted, before modern treatments were developed in the 1940s, said Dr. Mario Raviglione, director of the Stop TB Department of the World Health Organization.” The newspaper notes, “The WHO is now assisting India to combat the strain” (Anand, 6/19).